


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-13 (Canceled).

14. (New) A compound of formula



or a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

$-b^1=b^2-C(R^{2a})=b^3-b^4$ represents a bivalent radical of formula

$-CH=CH-C(R^{2a})=CH-CH=$ (b-1);

$-N=CH-C(R^{2a})=CH-CH=$ (b-2);

$-CH=N-C(R^{2a})=CH-CH=$ (b-3);

$-N=CH-C(R^{2a})=N-CH=$ (b-4);

$-N=CH-C(R^{2a})=CH-N=$ (b-5);

$-CH=N-C(R^{2a})=N-CH=$ (b-6); or

$-N=N-C(R^{2a})=CH-CH=$ (b-7);

q is 0, 1, 2, 3 or 4;

R^1 is hydrogen, aryl, formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl substituted with formyl, C_{1-6} alkylcarbonyl, or C_{1-6} alkyloxycarbonyl;

R^{2a} is cyano; aminocarbonyl; mono- or di(methyl)aminocarbonyl; C_{1-6} alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl; C_{2-6} alkenyl substituted with cyano; or C_{2-6} alkynyl substituted with cyano;

each R^2 independently is hydroxy, halo, C_{1-6} alkyl optionally substituted with cyano or $-C(=O)R^4$, C_{3-7} cycloalkyl, C_{2-6} alkenyl optionally substituted with one or more halogen atoms or cyano, C_{2-6} alkynyl optionally substituted with one or more halogen atoms or cyano, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_{1-6} alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, $-S(=O)_pR^4$, $-NH-S(=O)_pR^4$, $-C(=O)R^4$, $-NHC(=O)H$, $-C(=O)NHNH_2$, $-NHC(=O)R^4$, $-C(=NH)R^4$ or a radical of formula



wherein each A independently is N, CH or CR^4 ;

B is NH, O, S or NR^4 ;

p is 1 or 2; and

R^4 is methyl, amino, mono- or dimethylamino or polyhalomethyl;

L is C_{4-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, or C_{3-7} cycloalkyl, whereby each of said aliphatic groups is optionally substituted with one or two substituents independently selected from

(i) C_{3-7} cycloalkyl,

(ii) indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C_{1-6} alkyl, hydroxy, C_{1-6} alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethoxy or C_{1-6} alkylcarbonyl,

(iii) phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings is optionally substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R^2 ; or

L is $-X-R^3$ wherein

R^3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings is optionally substituted with two, three, four or five substituents each independently selected from the substituents defined in R^2 ; and

X is $-NR^1-$, $-NH-NH-$, $-N=N-$, $-O-$, $-C(=O)-$, $-CHOH-$, $-S-$, $-S(=O)-$ or $-S(=O)_2-$;
aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, cyano, nitro, polyhalo C_{1-6} alkyl or polyhalo C_{1-6} alkyloxy.

15. (New) A compound as claimed in claim 14 wherein L is $-X-R^3$, $-X-$ is $-O-$ or $-NH-$ and R^3 is phenyl substituted with two or three substituents each independently selected from chloro, bromo, cyano or methyl.

16. (New) A compound as claimed in claim 14 wherein R^{2a} is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C_{1-6} alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl.

17. (New) A method of treating a subject suffering from Human Immunodeficiency Virus (HIV) infection, comprising administering a therapeutically effective amount of a compound of claim 14 to said subject.

18. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compound as claimed in claim 14.

19. (New) A process for preparing a pharmaceutical composition as claimed in claim 18 comprising mixing a therapeutically effective amount of said compound with a pharmaceutically acceptable carrier.

20. (New) The combination of a compound as defined in claim 14 and another antiretroviral compound.

DOCKET NO.: JANS-0035

PATENT

Application No.: Not yet assigned

Preliminary Amendment - First Action Not Yet Received

21. (New) A combined preparation for simultaneous, separate or sequential use in anti-HIV treatment, comprising a product containing (a) a compound as defined in claim 14, and (b) another antiretroviral compound.

22. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 14, and (b) another antiretroviral compound.